Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
The 52-week study will enroll 320 participants across 47 centers in China to test whether the AI-discovered drug slows or reverses lung fibrosis.
- On Wednesday, Insilico Medicine dosed the first patient with Rentosertib in the GENESIS-IPF-3 Phase III clinical trial at Peking Union Medical College Hospital, with Shanghai Pulmonary Hospital enrolling its first participant simultaneously.
- Rentosertib, the world's first drug candidate discovered using generative AI, targets TNIK to treat idiopathic pulmonary fibrosis , a chronic, scarring lung disease affecting approximately 5 million people worldwide.
- This 52-week, multi-center Phase III study will enroll 320 participants across 47 centers in China, with the primary endpoint measuring the annual rate of decline in forced vital capacity over 52 weeks.
- Carol Satler, Senior Vice President for Clinical Development at Insilico Medicine, called Rentosertib "transformative to patient care," though the drug remains investigational and has not received approval from any regulatory authority.
- Insilico Medicine reported approximately $106 million in revenue during the first half of 2026, a 287% year-over-year increase, achieving its first profitable half-year since listing on the Hong Kong Stock Exchange.
25 Articles
25 Articles
Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis
Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.
The Courier-Tribune
Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
CAMBRIDGE, Mass., Sept. 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase…
In addition to lung disease, an active substance developed with generative AI against idiopathic pulmonary fibrosis could also influence age-related processes. In a small clinical sub-study, the biological age estimated by six blood protein models decreased under reindeertib. However, whether the body actually ages more slowly is still open. Cambridge (U.S.A.). The calendar age describes only how many years a person [...] The article AI-active s…
This AI-Designed Drug Just Entered Phase III Trials — And It Might Reverse Your Biological Age
Spread the loveImagine a future where the drugs you take aren’t just treating symptoms, but are fundamentally designed by artificial intelligence, from the very target they aim for to their molecular structure. Now, imagine one of these AI-conceived compounds not only making it to late-stage human trials but also showing intriguing signs of reversing biological aging. Sounds like science fiction, right? Well, that future is a lot closer than you might think. Insilico Medicine, a name you’ll be hearing a lot more often, recently announced a truly groundbreaking milestone: they’ve dosed the first patient in GENESIS-IPF-3, the world’s inaugural Phase […]
The first phase III study for the human test of a drug against idiopathic pulmonary fibrosis is initiated. The entry Molecules conceived integrally by AI enter a clinical trial was first published in Diario La R.
Coverage Details
Bias Distribution
- 83% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
